Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

被引：0
|
作者：
Caffo, O. [1 ]
Palesandro, E. [2 ]
Nole, F. [3 ]
Gasparro, D. [4 ]
Mucciarini, C. [5 ]
Aieta, M. [6 ]
Zagonel, V. [7 ]
Iacovelli, R. [8 ]
De Giorgi, U. F. F. [9 ]
Rossetti, S. [10 ]
Fratino, L. [11 ]
Ermacora, P. [12 ]
Nicodemo, M. [13 ]
Giordano, M. [14 ]
Sartori, D. [15 ]
Scapoli, D. [16 ]
Verri, E. [3 ]
Maines, F. [17 ]
Pappagallo, G.
Aglietta, M. [18 ]
机构：
[1] Osped Santa Chiara, Med Oncol, Trento, Italy
[2] IRCCS Candiolo, Dipartimento Oncol Med, Candiolo, Italy
[3] Ist Europeo Oncol, Med Oncol, Milan, Italy
[4] AOU Parma, Med Oncol, Parma, Italy
[5] Osped Ramazzini, Med Oncol, Carpi, Italy
[6] Ctr Riferimento Oncol Basilicata IRCCS, Med Oncol, Rionero In Vulture, Italy
[7] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy
[8] Fdn Policlin Agostino Gemelli, IRCCS, Rome, Italy
[9] Ist Tumori Romagna IRST, Dept Med Oncol, Meldola, Forli Cesena, Italy
[10] Fdn Pascale, Unita Dipartimentale Uroandrol, Naples, Italy
[11] CRO, Med Oncol, Aviano, Italy
[12] AOU Udine, Med Oncol, Udine, Italy
[13] Negrar Canc Ctr, Med Oncol, Negrar, Italy
[14] Presidio Osped Osped St Anna, Med Oncol, San Fermo Battaglia, Italy
[15] Osped Civiile Dolo, Med Oncol, Dolo, Italy
[16] Azienda Osped Ferrara St Anna, Med Oncol, Ferrara, Italy
[17] Osped Santa Chiara, Oncol, Trento, Italy
[18] Ist Candiolo FPO IRCCS, Med Oncol, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
854P
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [21] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
    Paredero Perez, I.
    Arnal, M.
    Lorente, D.
    Girones Sarrio, R.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Llacer Perez, C.
    Castro Marcos, E.
    Olmos, D.
    Sanchez Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
  • [23] TALAPRO-2: Phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Zschabitz, S.
    Agarwal, N.
    Azad, A. A.
    Carles, J.
    Fay, A. P.
    Matsubara, N.
    Heinrich, D.
    Szczylik, C.
    De Giorgi, U.
    Joung, Young J.
    Fong, P. C.
    Voog, E.
    Jones, R. J.
    Shore, N. D.
    Dunshee, C.
    Lin, X.
    Healy, C. G.
    Di Santo, N.
    Zohren, F.
    Fizazi, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 113 - 114
  • [24] Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial
    Araujo, John C.
    Trudel, Geralyn C.
    Saad, Fred
    Armstrong, Andrew J.
    Yu, Evan Y.
    Bellmunt, Joaquim
    Wilding, George
    McCaffrey, John
    Serrano, Sergio V.
    Matveev, Vsevolod
    Efstathiou, Eleni
    Oudard, Stephane
    Morris, Michael J.
    Sizer, Bruce
    Goebell, Peter J.
    De Bono, Johann Sebastian
    Paliwal, Prashni
    Durham, Susan
    Cheng, Shinta
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Giannakakou, Paraskevi
    Kirby, Brian J.
    Nicacio, Leonardo V.
    Eisenberger, Mario A.
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial
    Caffo, O.
    Sava, T.
    Comploj, E.
    Giampaolo, M.
    Zustovich, F.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    Valduga, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D)
    Peer, Avivit
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Boursi, Ben
    Leibowitz-Amit, Raya
    Berger, Raanan
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Pili, Roberto
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Beuzeboc, Philippe
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Greilsamer, Charlotte
    Hon, Thierry Nguyen Tan
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Ratta, Raffaele
    Flechon, Aude
    Cheneau, Caroline
    Maillard, Aline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    EUROPEAN UROLOGY, 2022, 81 (03) : 234 - 240
  • [29] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
    Bouman-Wammes, Esther W.
    de Munck, Linda
    van den Berg, H. Pieter
    Beeker, Aart
    Smorenburg, Carolien H.
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345